GeneDx (NASDAQ:WGS) Reaches New 52-Week High at $28.77

GeneDx Holdings Corp. (NASDAQ:WGSGet Free Report) shares hit a new 52-week high during mid-day trading on Thursday . The company traded as high as $28.77 and last traded at $28.77, with a volume of 253243 shares changing hands. The stock had previously closed at $27.28.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on WGS shares. TD Cowen increased their price objective on shares of GeneDx from $14.00 to $24.00 and gave the company a “buy” rating in a report on Tuesday, April 30th. The Goldman Sachs Group raised their target price on GeneDx to $11.00 and gave the company a “neutral” rating in a research note on Monday, April 15th. Jefferies Financial Group assumed coverage on shares of GeneDx in a research report on Monday, June 3rd. They issued a “hold” rating and a $21.00 price target on the stock. Finally, BTIG Research boosted their target price on shares of GeneDx from $15.00 to $19.00 and gave the stock a “buy” rating in a report on Tuesday, April 30th.

Read Our Latest Report on GeneDx

GeneDx Trading Up 5.5 %

The company has a fifty day simple moving average of $17.72 and a 200-day simple moving average of $9.47. The stock has a market cap of $751.47 million, a price-to-earnings ratio of -5.27 and a beta of 2.21. The company has a current ratio of 3.22, a quick ratio of 2.99 and a debt-to-equity ratio of 0.25.

GeneDx (NASDAQ:WGSGet Free Report) last issued its earnings results on Monday, April 29th. The company reported ($0.33) EPS for the quarter, topping the consensus estimate of ($0.68) by $0.35. The business had revenue of $62.42 million during the quarter, compared to analysts’ expectations of $49.80 million. GeneDx had a negative return on equity of 36.23% and a negative net margin of 60.86%. On average, research analysts forecast that GeneDx Holdings Corp. will post -0.92 earnings per share for the current fiscal year.

Insider Activity at GeneDx

In related news, Director Casdin Capital, Llc bought 50,000 shares of the business’s stock in a transaction on Monday, May 13th. The shares were bought at an average cost of $23.31 per share, for a total transaction of $1,165,500.00. Following the completion of the acquisition, the director now directly owns 2,753,509 shares in the company, valued at $64,184,294.79. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. In other news, Director Casdin Capital, Llc acquired 50,000 shares of GeneDx stock in a transaction dated Monday, May 13th. The stock was acquired at an average cost of $23.31 per share, for a total transaction of $1,165,500.00. Following the completion of the purchase, the director now owns 2,753,509 shares of the company’s stock, valued at $64,184,294.79. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Katherine Stueland sold 8,559 shares of the firm’s stock in a transaction on Monday, March 18th. The shares were sold at an average price of $10.59, for a total transaction of $90,639.81. Following the completion of the transaction, the chief executive officer now owns 66,698 shares in the company, valued at $706,331.82. The disclosure for this sale can be found here. In the last quarter, insiders bought 175,804 shares of company stock valued at $3,771,670 and sold 24,796 shares valued at $316,761. 28.10% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On GeneDx

Several hedge funds and other institutional investors have recently modified their holdings of WGS. Oracle Investment Management Inc. grew its position in GeneDx by 531.7% during the first quarter. Oracle Investment Management Inc. now owns 1,126,607 shares of the company’s stock worth $10,286,000 after buying an additional 948,253 shares in the last quarter. Gagnon Securities LLC increased its position in shares of GeneDx by 59.3% during the first quarter. Gagnon Securities LLC now owns 556,305 shares of the company’s stock valued at $5,079,000 after purchasing an additional 207,027 shares during the period. Decheng Capital LLC acquired a new position in shares of GeneDx in the fourth quarter valued at $285,000. Gagnon Advisors LLC boosted its stake in GeneDx by 41.6% during the first quarter. Gagnon Advisors LLC now owns 211,393 shares of the company’s stock worth $1,930,000 after buying an additional 62,059 shares in the last quarter. Finally, Pathstone Family Office LLC raised its stake in shares of GeneDx by 262.2% in the 3rd quarter. Pathstone Family Office LLC now owns 54,327 shares of the company’s stock valued at $198,000 after buying an additional 39,327 shares in the last quarter. Institutional investors and hedge funds own 61.72% of the company’s stock.

GeneDx Company Profile

(Get Free Report)

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.

Featured Articles

Receive News & Ratings for GeneDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GeneDx and related companies with MarketBeat.com's FREE daily email newsletter.